Isoflavones can exert their action on various levels: on cardiovascular system, bone and muscle health, on cancer, on menopausal symptoms, on obesity, on thyroid and on cognitive function. The aim of this systematic review is to evaluate the multidimensional effects of phytoestrogens in postmenopausal woman, and specifically to explore the impact on scientific literature. A research strategy was planned on PubMed and Scopus by defining the following key words:: menopause, climacteric, soy, isoflavone, phytoestrogens, cardiovascular system, bone mineral density, muscle mass, cancer, thyroid, obesity, cognitive. A total of 43 studies (in humans) were retrieved. The majority (12) describe the applications of soy isoflavones on cardiovascular disease, followed by effects on bone and muscle health (9), and studies concerning their action on menopausal symptoms (7), on cancer (6), on obesity (4), on cognitive function (3) and on thyroid function (2). The citation analysis revealed a growing interest for this topic and the papers on thyroid function are the most cited. Citation trends of the articles regarding the action on cardiovascular disease and on obesity are growing in the last years. Concerning the research areas, this review has assessed the effectiveness of various activities of isoflavones on welfare of menopausal women. In particular, literature show that a specific dosage of isoflavones reduces cardiovascular disease (from 20 to 100 mg/die), may be protective in osteoporosis and muscular fatigue (from 20 to 80 mg/die), may be useful for cancer prevention on endometrium, mammary glands and liver (from 50 to 100 mg/die), might improve menopausal symptoms, particularly in reducing the frequency of hot flashes (from 50 to 120 mg/die), can reduce abdominal fat and circulating inflammatory markers (from 80 to 160 mg/die), may ameliorate the possible interaction between endogenous estrogen and thyroid function (75 mg/die) and improve visual memory (from 50 to 100 mg/die).
Menopause is defined as the physiological event that in woman corresponds to the end of menstruation and childbearing. With the cessation of the menstrual cycle there are a sudden drop in estrogen levels, a disappearance of the cyclic production of progesterone and a marked increase in gonadotropins FSH and LH [1] .
Menopause may be accompanied by disorders that can be neuropsychological (insomnia, fatigue, irritability, anxiety, depression and strong mood disturbance) and vasomotor disturbances (hot flashes, night sweats, headaches, palpitations, dizziness) [1] , second to a drop in estrogen hormone.
Phytoestrogens are plant-derived chemicals that are structurally or functionally similar to estradiol (E2). There are many different classes of phytoestrogens, but the main type that has been given therapeutically to menopausal women is isoflavones [2] .
The major isoflavones are daidzein, equol and genistein [3] . Daidzein can be formed from formononetin, and in the gut is further metabolized to equol and O-desmethylangolensin (O-DMA). Genistein can be produced from biochanin A. Genistein, daidzein, equol and O-DMA can all be found in human blood [4] .
Phytoestrogens are found in high concentrations in soybeans (specially isoflavones) and, although in lower amounts, in many types of fruits, vegetables and whole grains [5] . Women need to take doses of 45-90 mg of soy isoflavones [6] , which means 2-3 servings of soy foods a day, to get the benefits. They can be found in nature in free form or in the form of glycosides; the latter need to be hydrolyzed by the intestinal bacterial flora in order to be absorbed [7] . Phytoestrogens can act at various levels:-cardiovascular system, -bone and muscle health,-on cancer,-on menopausal symptoms, -on obesity,-on thyroid function, and -on cognitive status.
The aim of this review was to evaluate the different multidimensional effects of phytoestrogens in postmenopausal women's health, and specifically to explore the dimension with a better scientific literature impact.
The present systematic review was performed according to the steps by Egger [8] (Table 1 ), as follows: (i) configuration of a working group: three operators skilled in soy phytoestogens in menopause women, of whom one acts as a methodological operator and two participating as clinical operators; (ii) formulation of the revision question on the basis of considerations made in the abstract: "action of soy phytoestrogens in postmenopausal women"; (iii) identification of relevant studies: a research strategy was planned, on PubMed and Scopus, as follows: (a) definition of the key words (menopause, climacteric, soy, isoflavones, phytoestrogens, cardiovascular system, bone mineral density, muscle mass, cancer, thyroid, obesity, cognitive), allowing the definition of the interest NPC Natural Product Communications field of the documents to be searched, grouped in inverted commas ("…") and used separately or in combination; (b) use of the Boolean AND operator, that allows the establishments of logical relationships among concepts; (c) research modalities: advanced search; (d) limits: papers published until November 2015; only humans studies; languages: English; (e) manual search performed by the senior researchers, experienced in clinical nutrition, through the revision of reviews and research articles on soy and phytoestrogens in menopause, published in qualified journals of the Index Medicus. Analysis and presentation of the outcomes: the data extrapolated from the revised studies are summarized in the tables. For each study we specified: the author and year of publication, the botanicals and the active principles, the models used, the posology, and the main results obtained. The analyses were carried out in the form of a narrative review of the reports. We consider several effects of soy phytoestrogens on various targets; we divided these effects into seven categories: action on the cardiovascular system, action on bone and muscle, action on cancer, action on menopausal symptoms, action on obesity, action on thyroid function, and action on cognitive functions. The flow diagram of this search is in Figure 1 . After this, we only classified the human data. Another key point was to identify the dosage of the soy phytoestrogens for each trial and the botanical compounds responsible for the activity. The use of databases such as Pubmed and Scopus was determinant to enrich our review. By the end, we reported an analysis of all soy phytoestegens that have a beneficial role in preventing menopausal symptoms and in other conditions related to menopause [8] . This analysis required processing the data to extract the relevant information about the object of the analysis, including scientific fields or disciplinary classification, and citation counting. The database selected for retrieving the publications was Scopus.
By modalities provided by Scopus, we searched for "soy, menopause, climacteric, soy, isoflavone, phytoestrogens, cardiovascular system, bone density, muscle mass, cancer, thyroid, obesity, cognitive, mental status".
Time limitations were specified in the search regarding the starting year (2010), and the ending date (October 31st, 2015). Reference lists of recent reviews were been searched for articles potentially missed during the electronic search. We performed a descriptive overview of all research articles in terms of subject category and citation counting. The citation counting period was between 2010 (for Scopus citation counting) and October 31st, 2015. Further analysis of citation was been performed on research articles that were been classified according to the research methodology (treatments): all research articles were classified according to the kind of soy phytoestrogen action; so, we classified research articles into seven groups.
Citation rate was calculated as follow: total citations for each article divided into years (from the beginning of publication, until now). In a second step, we calculated the citation rate into each category of action.
Action on cardiovascular system
This research has been based on the keywords "soy" AND "cardiovascular" AND "menopause"; 26 articles were sourced and 12 studies have been taken into consideration (Table 2) .
A recent article by Acharjee, examined the effects of diet with and without soy nuts (25 g of soy protein and 101 mg of isoflavones aglycone) on many cardiovascular parameters. Cardiovascular risk reduction with soy nuts was not uniform in the subjects studied and may be greater among women producers of equol, which is an inhibitor of oxidation of LDL and also inhibits inflammation [9] . Also Mangano et al. underline the importance of equol: the Action on cardiovascular system: n =12 -Action on bone and muscle mass: n =9 -Action on cancer: n =6 -Action on menopause symptoms: n =7 -Action on obesity: n =4 -Action on thyroid function: n= 2 -Action on cognitive status n =3
Full-text articles assessed for eligibility [n = 58 ] -Action on cardiovascular system: n =17 -Action on bone and muscle mass: n =14 -Action on cancer: n =7 -Action on menopause symptoms: n =10 -Action on obesity: n =4 -Action on thyroid function: n=3 -Action on cognitive status n =3
Effects of soy phytoestrogens by food and supplements in menopause women Natural Product Communications Vol. 11 (11) isoflavone aglycone equivalents) into the diets of healthy postmenopausal women should not be considered an effective intervention to prevent cardiovascular disease, because it depends on the ability to produce equol [10] . As regards to a nutraceutical approach to dietary supplements, based on a combination of isoflavones (60 mg) and barberine, a decreased level of MMP-2 (Matrix MetalloProteinase-2) and MMP-9 (Matrix MetalloProteinase-9), is strongly associated with cardiovascular risk factors [11] . D'Anna et al. tested the effect of a new supplement formula, combining cocoa polyphenols, myo-inositol, and soy isoflavones (80 mg), which improved some biomarkers of cardiovascular risk in postmenopausal women with metabolic syndrome [12] . However, concerning cardiovascular risk and lipid profile, no effect was found in two recent studies performed by Liu et al. [13] and Ye et al. [14] .
It is possible that isoflavones (70 mg or 35 mg soy extract) may contribute to a lower risk of CVD in conjunction with other lipidlowering strategies, thanks either to their direct effects or antioxidant properties [15] . Pusparini et al. underline that soy isoflavones intake (100 mg of soy isoflavones) for 6 and 12 months had an effect on oxidative stress by decreasing MDA concentration, [16] . In the study of Wong there was no correlation among nitric oxide metabolism, blood pressure and soy isoflavones [17] . A supplementation with isoflavone soy protein (25 g soy protein containing 91 mg isoflavone aglycon equivalents) had no effect on subclinical atherosclerosis progression on women who were >5 years beyond menopause, so this suggests a potential benefit over a narrower age range [18] . Kim et al. underline that supplementation with isoflavone (70 mg) reduced serum levels of TG and LH, because isoflavone seems to have a higher affinity for the ER-b (estrogen breceptor) than the ER-a receptor (estrogen a-receptor). Isoflavone possesses dual effects, both estrogenic and anti-estrogenic; however, whether it acts primarily as an estrogen or as an antiestrogen appears to depend on the levels of circulating estrogens and types of ERs in individuals [19] . In conclusion, the studies concerning this topic provide evidence that a daily supplementation of soy isoflavones (20-100 mg/die) ameliorates the cardiovascular risk, especially by reducing cholesterol and triglycerides and reduction in terms of oxidative stress evaluated with serum nitric oxide (NO) and malondialdehyde (MDA) as oxidative stress markers.
Action on bone and muscle
This research has been carried out on the keywords "soy" AND "bone" OR "muscle mass" AND "menopause"; 15 articles were sourced and 9 studies have been taken into consideration.
No effect was found to prevent a decline in Body Mass Density (BMD) in the lumbar spine or total femur with 300-mg/day isoflavones [20] . Also, Levis et al. [21] and Alekel et al. [22] did not find any association between soy isoflavones and bone mass loss. However, Tousen et al. [23] demonstrated that natural S-equol (a metabolite of the isoflavone daidzein) supplementation (10 mg/die) inhibits bone resorption by osteoclasts and prevents the decrease in bone mineral density (BMD) in the entire women's body. Afterwards, Yang et al. [15] underlined a positive effect on the skeleton, using either 35 mg or 70 mg soy extract (17.5 mg or 35 mg of isoflavones) daily for 24 weeks, because isoflavones have a short-term effect on bone sparing. D'Anna et al. [12] tested the effect of a new supplement formula, combining cocoa polyphenols, myo-inositol, and soy isoflavones (80 mg), which improves some biomarkers of cardiovascular risk and increases bone formation in postmenopausal women with metabolic syndrome. Pawlowski et al. [24] showed that soy isoflavones are effective bone-preserving agents in postmenopausal women regardless of their equolproducing status. Choquette et al. [25] did not find a positive correlation between isoflavones (70 mg/day) and muscle, instead of exercise. In conclusion, there are some contradictory results from the studies analyzed, even if it was demonstrated that an oral daily supplementation with soy isoflavones (20-80 mg) and S-equol (10 mg) may be protective in bone resorption.
No significant results were found about action on muscle mass.
Action on cancer
This research has been carried out based on the keywords "soy" AND "neoplastic" AND "menopause"; 15 articles were sourced and 6 studies have been taken into consideration (Table 4) . , probably because it predominantly acts on the beta-type estrogen receptor (ER-β), but the main estrogen receptor in the endometrium is the alpha-type (ER-α), as well as the main mediator of endometrial hyperplasia and cancer risk [29] . In conclusion, almost all the studies taken into account support the concept that a daily supplementation of soy isoflavones (50-150 mg/die) may be protective against the occurrence of cancer in menopausal women, particularly in the endometrium, mammary glands and liver.
Action on menopausal symptoms
This research has been carried out on the keywords "soy" AND "menopause" AND "symptoms"; 38 articles were sourced and 7 studies have been taken into consideration (Table 5 ).
Jenks et al. have proposed that S-equol, a metabolite of the soy isoflavone daidzein, has a potential role for relief of menopausal symptoms, comparing the natural S-equol supplement, SE5-OH, with isoflavones for relieving hot flashes and other menopausal symptoms. This study, conducted on 102 postmenopausal women, has concluded that S-equol, with a dosage of 10 mg/day, appears to be as effective as soy isoflavones in reducing hot flush frequency. Furthermore, S-equol at 20 mg/day alleviates hot flushes to a greater extent than soy isoflavones in women who experienced >8 hot flushes/day. [30] Another study conducted in 2012 by Ye et More recently, Cicero et al. have evaluated the efficacy and tolerability of a combined nutraceutical approach on a large number of menopausal symptoms in healthy, dyslipidemic, postmenopausal women. This was a controlled, single blinded, randomized, perspective study with parallel groups, in which 40 women were randomized to treatment with either a nutraceutical containing soy isoflavones (60 mg) and berberine (500 mg) or a placebo. At the end, there was a significant improvement in menopausal symptoms beyond palpitation, as well as in plasma and serum lipids, in the isoflavones-berberine-treated group [11] . For Amato et al. [33] soy isoflavone supplementation offered no benefit to the quality of life of postmenopausal women.
In conclusion, there is evidence supporting the concept that soy germ, with its isoflavones, (50-120 mg/die), might improve Effects of soy phytoestrogens by food and supplements in menopause women Natural Product Communications Vol. 11 (11) 2016 1737 
Action on obesity
This research has been carried out on the keywords "soy" AND "menopause" AND "obesity"; 5 articles were sourced and 4 studies have been taken into consideration (Table 6 ). , in which it was demonstrated that a soy isoflavones supplementation (80 mg/day), with physical exercise and Mediterranean Diet, decreased some characteristic parameters of Metabolic Syndrome such as serum leptin and TNF-α levels, BMI, fat mass, glucose, insulin, HOMA-IR and also increased the production of adiponectin, which suggesting a protective role of isoflavones on obesity and particularly on abdominal fat and fat mass [36, 37] .
In conclusion, all these studies demonstrated that a daily supplementation with isoflavones (80-160 mg/die) can improve many parameters characteristic of menopause, including increased abdominal fat and increased circulating inflammatory markers such as tumor necrosis factor (TNF-α) and interleukin-6 (Il-6), which are some of the important metabolic cardiovascular risk factors.
Action on thyroid function
This research has been carried out on the keywords "soy" AND "thyroid" AND "menopause"; 5 articles were sourced and 2 studies has been taken into consideration (Table 7) . Between these, one study, by Mittal et al., showed a significant change (modest reduction) in free T3 levels in the isoflavone group. This group also demonstrated an improvement in urogenital symptoms compared with placebo. [38] A number of potential mechanisms by which isoflavones interact with thyroid gland include interference with enterohepatic circulation of thyroxine [39] , competition with thyroid hormones for thyroid sulfotransferase enzymes [40] , inhibition of thyroid peroxidase [41] and interference with thyroid hormone synthesis by inhibition of iodide uptake and organification. Significant alteration in free T3 levels was found. Besides, isoflavones led to immune dysfunction by causing potent stimulation of T cell and B cell mediated immunity due to induced structural changes in thyroid peroxidase. [42] . In conclusion, there is only one study concerning this topic by which isoflavone (75 mg/die) is shown to ameliorate the possible interaction between endogenous estrogen and thyroid function. Consideration should be given to avoid this supplementation to women who have an iodine deficiency.
Action on cognitive status
This research has been carried out on the keywords "soy" AND "cognitive" AND "menopause"; 12 articles were sourced and 3 studies have been taken into consideration ( influencing noradrenergic transmission, the final pathway and that soybean has an antidepressant effect "per se", and the association of soybean and antidepressants increases their effects. [43] .
In a recent study by Henderson et al. on postmenopausal women, long-term dietary soy isoflavone supplementation at a dose comparable with that of traditional Asian diets had no effect on global cognition, but may improve visual memory [44] . In accordance with this, the study of Gleason et al. showed that 6 months of 100 mg/day treatment with soy isoflavones did not benefit cognition in older men and women with Alzheimer's disease [45] . In conclusion, both studies concerning this topic provide evidence that long-term dietary supplementation with isoflavones (50-100 mg/die) does not improve global cognition of postmenopausal women, but may improve visual memory. Table 9 shows the citation rate by year for each category of action. The highest citation rate was found in the category of action on thyroid function (4.00). This is interesting, but we have to notice that there are limited studies in this category. This ranking shows a high citation rate also for the category of action on cardiovascular risk (3.14) and obesity (2.02). Minor citation rates were observed in the categories of action in bone and muscle (1.94) and cancer (1.71). Menopause is a significant event in the lives of most women, as it marks the end of a woman's natural reproductive life.
Bibliometric analysis
Concerning the research areas (cardiovascular, bone and muscle health, cancer, menopausal symptoms, obesity, thyroid function, cognitive status), this review has assessed the effectiveness of various activities of isoflavones on the welfare of menopausal women. The principle symptoms of menopause can be well managed through the administration of phytoestrogens, which leads to an improvement in the frequency of hot flushes, and psychosomatic symptoms like insomnia, fatigue and sexual dysfunction [14, [30] [31] [32] . Regarding the interaction between thyroid hormones and phytoestrogen, there is no significant evidence, but our bibliometric analysis shows an interest in this topic, which could be discussed further with better future studies. As shown in the study of Tounsen et al., the effects on the thyroid can also be associated with bone metabolism and bone resorption by osteoclasts [23] . The results of bone and muscle are still poorly studied and contradictory, although there is a constant interest in the scientific community. Instead there are no relationships with the trophic muscle, as shown in the study of Choquette et al. [25] On the contrary, the effects on cardiovascular prevention are evident, especially in the reduction of cholesterol and triglycerides and reduction in terms of oxidative stress [16] . Furthermore, soy isoflavones decrease the production of pro-inflammatory cytokines TNF-A and INT-6, exerting a positive action against visceral obesity [34, 36, 37] .
Finally, a possible application of isoflavones could be represented in the prevention of symptoms related to cognitive impairment. Encouraging results have been observed in visual memory [44] . In conclusion, phytoestrogens, and in particular soy isoflavones, are a safe integration as a therapy alongside Hormone Replacement Therapy (HRT).
